CNPR Drug Development Process 3 — Questions and Answers
Question 1: Which of the following best describes the role of a 'placebo' in a controlled clinical trial?
- A low-dose version of the investigational drug
- An inactive substance used to eliminate bias when comparing treatment effects (Correct answer)
- A generic equivalent of the brand-name drug
- A rescue medication given to patients who fail treatment
Correct answer: An inactive substance used to eliminate bias when comparing treatment effects
A placebo is an inert treatment that controls for the psychological effects of receiving treatment, allowing true drug effects to be isolated.
Question 2: What is the 'patent cliff' in the pharmaceutical industry?
- The steep increase in R&D spending during Phase III trials
- The sharp revenue decline a brand drug experiences when its patent expires and generics enter (Correct answer)
- The regulatory delay caused by FDA review backlogs
- The drop in stock price after a failed clinical trial
Correct answer: The sharp revenue decline a brand drug experiences when its patent expires and generics enter
When a blockbuster drug loses patent protection, generic competitors rapidly erode market share, causing a steep revenue drop known as the patent cliff.
Question 3: Post-marketing surveillance studies conducted after FDA approval are categorized as:
- Phase I studies
- Phase II studies
- Phase III studies
- Phase IV studies (Correct answer)
Correct answer: Phase IV studies
Phase IV studies occur after a drug is approved and marketed, monitoring long-term safety and effectiveness in the general population.
Question 4: Which document must a pharmaceutical sales representative provide to a healthcare provider that summarizes FDA-approved prescribing information?
- The Investigator's Brochure
- The Package Insert (PI) / Prescribing Information (Correct answer)
- The Clinical Study Report
- The Common Technical Document
Correct answer: The Package Insert (PI) / Prescribing Information
The package insert (prescribing information) is the FDA-approved label containing indications, dosing, contraindications, warnings, and clinical data.
Question 5: The FDA's 'Orphan Drug Act' provides incentives for developing drugs that treat diseases affecting fewer than how many people in the US?
- 100,000
- 200,000 (Correct answer)
- 500,000
- 1,000,000
Correct answer: 200,000
The Orphan Drug Act defines rare diseases as those affecting fewer than 200,000 people in the US and provides tax credits, grants, and 7-year market exclusivity.
Question 6: In clinical research, what does 'double-blind' mean?
- Neither the patient nor the investigator knows which treatment the patient is receiving (Correct answer)
- The study uses two different placebo formulations
- Both the sponsor and FDA are blinded to interim results
- The drug is tested in two separate patient populations simultaneously
Correct answer: Neither the patient nor the investigator knows which treatment the patient is receiving
In a double-blind study, both participants and researchers are unaware of treatment assignments, minimizing bias in assessment and reporting.
Question 7: What is the standard FDA review period for a Priority Review application?
- 6 months (Correct answer)
- 10 months
- 12 months
- 18 months
Correct answer: 6 months
Priority Review reduces the standard 10-month review period to 6 months for drugs offering major advances over available therapies.
CNPR Drug Development Process 3
Which of the following best describes the role of a 'placebo' in a controlled clinical trial?